Ann: Approval received for final stage of NNZ-2591 clinical trial, page-19

The CEO makes the comment in the interview that by the end of 2021, Neuren could have one product completed Phase 3 and looking for approval and four follow-ups in Phase 2 getting close to data. Lets look at the three follow-ups that relate to NNZ-2591.

Of course we have to start off with an IF.

If the pivotal Rett Syndrome trial for Trofinetide is successful, that data for NNZ-2591 could become some of the most highly anticipated data in the neurological space. The two compounds share so much in common but its the tweaked differences that will raise expectations. If Trofinetide goes on to gain approval, all eyes will be on Trofinetide mark 2. The pioneer will have blazed the trail into the neuro-degenerative, neuro-developmental and neuro-protective space but a potentially better therapeutic from the same stable of compounds is hot on its heels. At the same time that Trofinetide is expected to gain approval triggering milestone payments, Neuren will have a war chest of funds to develop NNZ-2591 in multiple indications.